Wells Fargo analyst Cerena Chen downgraded Metsera (MTSR) to Equal Weight from Overweight with a price target of $54, down from $65, after Pfizer (PFE) announced an agreement to acquire Metsera for $4.9B upfront and total potential deal value of about $7.3B contingent on hitting various pipeline-related targets. The firm adds that here’s little likelihood of other bidders coming in at this time as other players have likely already looked at the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MTSR:
- Metsera reports ‘positive’ Phase 2b results for GLP-1 RA candidate MET-097i
- Metsera downgraded to Market Perform from Outperform at Leerink
- Pfizer gains ‘impressive obesity portfolio’ with Metsera deal, says BofA
- Metsera rises 62.3%
- Pfizer’s Metsera deal provides positive readthrough to Viking, says BTIG